InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
2.090
-0.080 (-3.69%)
At close: Sep 9, 2026, 4:00 PM EDT
2.090
0.00 (0.00%)
After-hours: Sep 9, 2026, 5:55 PM EDT
InflaRx Revenue
InflaRx had revenue of -10.10K EUR in the twelve months ending June 30, 2026. In the year 2025, InflaRx had annual revenue of 29.33K, down -82.31%.
Revenue (ttm)
-10.10K EUR
Revenue Growth
-82.31%
P/S Ratio
-26,689.74
Revenue / Employee
-155 EUR
Employees
65
Market Cap
308.00M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.33K | -136.46K | -82.31% |
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Sutro Biopharma | 45.70M |
| Orchestra BioMed Holdings | 31.98M |
| Abeona Therapeutics | 25.52M |
| Pyxis Oncology | 11.04M |
| Upstream Bio | 3.16M |
| Vicore Pharma Holding AB | 412.09K |
| SAB Biotherapeutics | 114.70K |
IFRX News
- 20 days ago - InflaRx Announces Participation in September Investor Conferences - GlobeNewsWire
- 4 weeks ago - InflaRx Earnings release: Q2 2026 - Filings
- 4 weeks ago - InflaRx files $250M mixed securities shelf - TheFly
- 4 weeks ago - InflaRx Registration statement: Registration filing - Filings
- 4 weeks ago - InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 5 weeks ago - InflaRx to Report Second Quarter 2026 Results on August 6, 2026 - GlobeNewsWire
- 2 months ago - InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos - GlobeNewsWire
- 3 months ago - InflaRx upgraded to Strong Buy from Outperform at Raymond James - TheFly